RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
806. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E,
Ballantyne CM, Pownall HJ y cols. Effects of sirolimus on
plasma lipids, lipoprotein levels, and fatty acid metabolism
in renal transplant patients. J Lipid Res 43: 1170-1180, 2002
807. McCune TR, Thacker LRII, Peters TG, Mulloy L, Rohr MS,
Adams PA, y cols. Effects of tacrolimus on hyperlipidemia
after successful renal transplantation: A Southeastern Organ
Procurement Foundation multicenter clinical study.
Transplantation 65: 87-92, 1998
808. Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy
M, y cols. Randomized trial of tacrolimus (Prograf) in combination
with azathioprine or mycophenolate mofetil after
cadaveric kidney transplantation. Transplantation 69: 834-
841, 2000
809. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F,
Ekberg H. Double blind comparison of two corticosteroid
regimens plus mycophenolate mofetil and cyclosporine for
prevention of acute renal allograft rejection. Transplantation
70: 1352-1359, 2000
810. Breyer JA, Bain RP, Evans JK, Nahman NS Jr, Lewis EJ,
Cooper M, y cols. Predictors of the progression of renal
insufficiency in patients with insulin dependent diabetes and
overt diabetic nephropathy. The Collaborative Study Group.
Kidney Int 50: 1651-1658, 1996.
811. Ravid M, , Brosh D, Ravid-Safran D, Levy Z, Rachmani R.
Main risk factors for nephropathy in type 2 diabetes mellitus
are plasma cholesterol levels, mean blood pressure, and
hyperglycemia. Arch Intern Med 158: 998-1004, 1998
812. Shearer GC, Stevenson FT, Atkinson DN, Jones H, Staprans I,
Kaysen GA . Hypoalbuminemia and proteinuria contribute
separately to reduce lipoprotein catabolism in the nephritic
syndrome. Kidney Int 59: 179-189, 2001
813. Murdoch SJ, Breckenridge WC. Influence of lipoproteinlipase
and hepatic lipase on the transformation of VLDL and
HDL during lipólisis of VLDL. Atherosclerosis 118: 193-212,
1995
814. Saski A, Goldberg IJ. Lipoprotein lipase release from BCF-1
beta adipocytes. Effects of triglyceride rich lipoproteins and
lipolysis products. J Biol Chem 267: 15198-15204, 1992
815. Liang K, Vaziri ND. Down regulation of hepatic lipase expresión
in experimental nephritic syndrome. Kidney Int 51:
1933-1937, 1997
816. Lambert G,Sakai N, Vaisman BL, Neufeld EB, Marteyn B,
Chan CC, y cols. Analysis of glomerulosclerosis in lecithin
cholesterol acyltransferase deficient mice. J Biol Chem 276:
15090-15098, 2001
817. Apple G. Lipid abnormalities in renal disease. Kidney Int
39: 169-183, 1991
818. De Sain van der Velden MG, Reijngoud D, Kaysen GA,
Gadellaa MM, Voorbij H, Stellaard F, y cols. Evidence for
increased synthesis of lipoprotein(a) in the nephrotic syndrome.
J Am Soc Nephrol 9: 1474-1481, 1998
819. Noel LH. Morphological features of primary focal and segmental
glomerulosclerosis. Nephrol Dial Transplant 14
(suppl 3): 53-57, 1999
820. Magil AB. Interstitial foam cells and oxidized lipoprotein in
human glomerular disease. Mod Pathol 12: 33-40, 1999
821. Suzuki S, Takahashi H, Sato H, Takashima N, Arakawa M,
Gejyo F. Significance of glomerular deposition of apolipoprotein(a)
in various glomerulopathies. Am J Nephrol 17:
499-504, 1997
822. Galle J, Stunz P, Schollmeyer P, Wanner C. Oxidized LDL
and lipoprotein(a) stimulate renin release of yuxtaglomerular
cells. Kidney Int 47: 45-52, 1995
823. Keane WF, O´Donnell MP, Kasiske BL, Kim Y. Oxidative
modification of low density lipoproteins by mesangial cells.
J Am Soc Nephrol 4: 187-194, 1993
824. Galle J, Heermeier K. Angiotensin II and oxidized LDL. An
unholy alliance creating oxidative stress. Nephrol Dial
Transplant 14: 2585-2589, 1999
825. Wheeler DC, Chana RS, Interactions between lipoproteins,
glomerular cells an matrix. Miner Electrolyte Metab 19: 149-
164, 1993
826. Palmer BF, Alpern RJ. Treating dyslipidemia to show the progresión
of chronic renal failure. Am J Med 114: 411-412,
2003
827. Abrass CK. Cellular lipid metabolism and the role of lipids in
progressive renal disease. Am J Nephrol 24: 46-53, 2004
828. Atchley DH, Lopes Virella MF, Zheng D, Kenny D, Virella G.
Oxidized LDL antioxidized LDL immune complexes and
diabetic nephropathy. Diabetologia 45: 1562-1571, 2002
829. Yorioka N, Taniguchi Y, Nishida Y, Okushin S, Amimoto D,
Yamakido M. Low density lipoprotein apheresis for focal
glomerular sclerosis. Ther Apher 1: 370-371, 1997
830. Yokoyama K, Sakai S, Sigematsu T, Takemoto F, Hara S,
Yamada A y cols. LDL adsorption improves the response of
focal glomerulosclerosis to corticosteroid therapy. Clin
Nephrol 50: 1-7, 1998
831. Walker WG. Hypertension related renal injury: A major contributor
to end stage renal disease. Am J Kidney Dis 22: 164-
173, 1993
832. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T,
Kusek JW y cols. Predictors of the progression of renal disease
in the Modification of Diet in Renal Disease Study.
Kidney Int 51: 1908-1919, 1997
833. Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC. The
10 year incidence of renal insufficiency in people with type
1 diabetes. Diabetes Care 22: 743-751, 1999
834. Hovind P, Rossing P,Tarnow L, Smidt UM, Parving HH. y
cols. Progression of diabetic nephropathy. Kidney Int 59:
702-709, 2001.
835. Massy ZA, Khoa TN, Lacour B, Descamps-Latscha B, Man
NK, Jungers P. Dyslipidaemia and the progression of renal
disease in chronic renal failure patients. Nephrol Dial
Transplant 14: 2392-2397, 1999
836. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R,
Mulec H, Wedel H y cols. Plasma level of lipoprotein(a) do
not predict progression of human chronic renal failure.
Nephrol Dial Transplant 11: 2237-2243, 1996
837. Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M,
Babazono T y cols. Predictors of the progression of diabetic
nephropathy and the beneficial effect of angiotensin converting
enzyme inhibitors in NIDDM patients. Diabetologia 40:
405-411, 1997
838. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G,
Buccianti G y cols. Proteinuria and blood pressure as causal
components of progression to end stage renal failure.
Nephrol Dial Transplant 1996; 11: 461-467, 1996
839. Orchard TJ, Forrest KY, Kuller LH, Becker DJ; y cols.
Pittsburgh Epidemiology of Diabetes Complications Study.
Lipid and blood pressure treatment goals for type 1 diabetes:
10 year incidence data from the Pittsburgh Epidemiology of
212